🟣 In a severe allergic reaction, the most urgent assessment priority is airway and breathing.

🟣 Dyspnea can indicate bronchospasm or airway edema, which can rapidly progress to respiratory failure.

🟣 Breathing difficulty is a critical warning sign because oxygenation can deteriorate quickly and become life-threatening.

🟣 The nurse prioritizes dyspnea because it guides immediate interventions such as oxygen support, airway management, and emergency medications.

🟣 Even if other symptoms are present, dyspnea signals potential anaphylaxis progression and demands rapid action.

Hypotension:

🟣 Hypotension is serious and can occur in anaphylaxis, but airway compromise can become fatal even faster if not addressed immediately.

🟣In priority frameworks, breathing concerns typically come before circulation if the airway is threatened.

Rhinorrhea:

🟣Runny nose is common in allergies but is not an emergency indicator.

🟣It does not suggest immediate airway obstruction or respiratory collapse.

Urticaria:

🟣Hives indicate histamine release but are not the most life-threatening finding.

🟣 Skin manifestations are lower priority compared with respiratory compromise.

Histamine is released following allergen exposure.

💎 Allergic rhinitis is an IgE-mediated process where allergen exposure triggers mast cell degranulation.

💎 This releases histamine, which causes sneezing, itching, watery eyes, and increased nasal secretions.

💎 Histamine is the key mediator that produces many classic allergy symptoms.

A person has an initial exposure to an antigen.

💎 The first exposure sensitizes the immune system by producing IgE antibodies against the allergen.

💎 IgE binds to mast cells, preparing the body for a stronger response on re-exposure.

💎 This sensitization step is required before typical allergic rhinitis symptoms occur on later exposure.

Exposure as a result of an allergen produces inflammation.

💎 When the allergen is encountered again, immune mediators trigger localized inflammation in the nasal passages.

💎 This inflammation causes swelling, congestion, and increased mucus production.

💎 The inflammatory response explains why symptoms can persist while exposure continues.

Nasal mucosa become inflamed.

💎 Histamine and other mediators increase capillary permeability, causing mucosal edema and irritation.

💎 Inflamed nasal mucosa leads to congestion, sneezing, and rhinorrhea.

💎 This is a hallmark physical change in allergic rhinitis.

The weather is cold during the winter.

💎 Cold weather can irritate airways, but it is not the mechanism of allergic rhinitis.

💎 Allergic rhinitis is triggered by allergen exposure, not temperature alone.

🔶 Allergy symptoms occur when allergen exposure triggers an antigen–antibody (IgE) reaction on mast cells.

🔶 This causes mast cell degranulation and histamine release, which drives many allergy manifestations.

🔶 Histamine increases capillary permeability and stimulates mucus secretion, leading to rhinorrhea and swelling.

🔶 It also stimulates nerve endings, causing itching and sneezing.

🔶 Because histamine is the key mediator, many allergy treatments focus on blocking H1 receptors to reduce symptoms.

Production of antibodies:

🔶 Antibody production is part of sensitization, but it does not directly cause the immediate symptoms.

🔶 Symptoms occur primarily during re-exposure when mediators like histamine are released.

Release of antihistamines:

🔶 The body does not release antihistamines as part of the allergic response.

🔶 Antihistamines are medications given to block histamine effects.

Suppression of histamine:

🔶 Histamine is not naturally suppressed during the reaction; it is released and causes symptoms.

🔶 Suppressing histamine would reduce symptoms rather than create them.

✅ Guaifenesin is a common OTC expectorant used to help clear mucus from the airways.

✅ It works by increasing hydration of respiratory secretions, making mucus thinner and easier to cough up.

✅ This supports a more productive cough and reduces chest congestion.

✅ It is commonly found in cough and cold products labeled “mucus relief” or “chest congestion.”

✅ Clients should be taught to increase fluid intake (if not contraindicated) to enhance mucus thinning and effectiveness.

Diphenhydramine:

✅Diphenhydramine is an antihistamine used for allergy symptoms and can cause sedation.

✅ It does not act as an expectorant to thin mucus for coughing.

Codeine:

✅ Codeine is an opioid that can act as an antitussive by suppressing the cough reflex.

✅ It does not loosen mucus and is not classified as an expectorant.

Dextromethorphan:

✅Dextromethorphan is a non-opioid antitussive that suppresses cough.

✅ It does not thin secretions like an expectorant does.

🔷 Sympathomimetic bronchodilators (like albuterol) stimulate beta-adrenergic receptors, which can cause temporary tachycardia and a “jittery/panicky” feeling.

🔷 These effects are common shortly after initiation because systemic absorption can briefly increase sympathetic stimulation.

🔷 Reassuring the patient is appropriate when symptoms match expected medication effects and the patient is otherwise stable.

🔷 The nurse should still assess the patient’s heart rate, blood pressure, and respiratory status to confirm the reaction is mild and expected.

🔷 Teaching reduces anxiety, improves adherence, and helps the patient distinguish expected effects from dangerous reactions like chest pain or severe palpitations.

Stop treatment and notify the healthcare provider:

🔷Stopping immediately is not necessary if the patient is having expected transient effects and remains stable.

🔷Notifying the provider is reserved for severe symptoms like chest pain, dysrhythmias, or significant instability.

Add more diluents to the nebulizer:

🔷Diluting the medication does not correct the pharmacologic cause of beta stimulation.

🔷It also risks altering the prescribed dose delivery and is not a standard nursing intervention.

Administer a sedative:

🔷Sedation is inappropriate for a predictable medication side effect and may worsen respiratory status.

🔷The priority is monitoring and reassurance, not suppressing CNS function.

🟢 Zafirlukast is a leukotriene modifier used for asthma maintenance by reducing the effects of leukotrienes, inflammatory mediators that cause bronchoconstriction and airway edema.

🟢 Leukotrienes contribute to airway inflammation, mucus production, and increased bronchial reactivity.

🟢 By blocking leukotriene activity, zafirlukast helps prevent asthma symptoms and improves long-term control.

🟢 It is not a rescue drug; it works best when taken regularly to prevent flare-ups.

🟢 Teaching should emphasize consistent use and monitoring for adverse effects like liver-related symptoms.

Dilates the alveolar sacs:

🟢Alveoli are not the main target for asthma bronchodilation, and zafirlukast does not directly dilate structures.

🟢Its primary effect is on inflammatory mediator pathways, not immediate airway dilation.

Inhibits histamine release:

🟢Histamine release is more closely associated with mast cell stabilizers or antihistamines, not leukotriene modifiers.

🟢Zafirlukast does not function as an antihistamine.

Increases viscosity of secretions:

🟢Leukotriene modifiers do not thicken secretions; airway inflammation typically increases mucus production, and treatment aims to reduce this.

🟢Increased viscosity would worsen airway clearance rather than improve asthma control.

🟣 Albuterol is a short-acting beta₂-agonist that provides rapid bronchodilation in the lower airways.

🟣 It relaxes bronchial smooth muscle, quickly relieving bronchospasm and improving airflow.

🟣 This makes it the standard rescue medication for acute asthma symptoms or sudden wheezing.

🟣 Relief usually occurs within minutes, which is why it is carried for quick symptom control.

🟣 Nursing teaching includes using it for acute symptoms and seeking care if frequent rescue use is needed, which can signal poor control.

Dyspnea on exertion:

🟣Exertional dyspnea can have many causes and is not specific to bronchospasm.

🟣Albuterol helps only if the dyspnea is due to reversible airway narrowing.

Acute allergies:

🟣 Allergic reactions involve histamine and immune pathways; albuterol does not treat systemic allergic processes.

🟣It may help wheezing from allergic asthma, but it is not an allergy medication.

Nasal congestion:

🟣Nasal congestion is treated with decongestants or intranasal steroids, not beta₂ bronchodilators.

🟣Albuterol targets bronchial smooth muscle, not nasal mucosa.

🔶 Respiratory tract secretions are produced by specialized mucus-producing cells, especially goblet cells in the airway epithelium.

🔶 Goblet cells secrete mucus that traps dust, microbes, and particles for clearance by the cilia (mucociliary escalator).

🔶 This secretion is a normal protective function that helps maintain airway moisture and defense.

🔶 When irritated or inflamed, goblet cells can increase mucus production, contributing to congestion and cough.

🔶 Understanding the mucus source helps explain why airway inflammation leads to excessive secretions in respiratory illness.

Cells that produce aqueous humor:

🔶Aqueous humor is produced in the eye and is unrelated to respiratory fluids.

🔶These cells do not contribute to airway mucus or respiratory secretions.

Specialized beta cells in the islets of Langerhans:

🔶Beta cells are pancreatic cells that produce insulin, not respiratory secretions.

🔶They have no role in airway fluid production.

Lymph fluid drawn across nasal membranes by osmosis:

🔶Respiratory mucus is not primarily formed by lymph pulled across membranes.

🔶Secretions are generated by mucous glands and goblet cells within respiratory mucosa.